Evidence map›Paper›PMID 38317159›Full record

ArticleRespiratory research2024

HDAC6-selective inhibitor CAY10603 ameliorates cigarette smoke-induced small airway remodeling by regulating epithelial barrier dysfunction and reversing.

Qin Zhang, Liming Yan, Ye Lu, Xiaodong Liu, Yan Yin, Qiuyue Wang, Xiu Gu, Xiaoming Zhou

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The role and mechanism of histone deacetylase in COPD.Molecular and cellular biochemistry · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qin Zhang *National Center for Respiratory Medicine, Shenyang, China.
Liming Yan *Department of Pulmonary and Critical Care Medicine, Fourth Hospital of China Medical University, Shenyang, China.
Ye Lu *Department of Respiratory and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Xiaodong LiuDepartment of Respiratory and Critical Care Medicine, Shengjing Hospital of China Medical University, Shenyang, China.
Yan YinDepartment of Respiratory and Critical Care Medicine, First Hospital of China Medical University, Shenyang, China.
Qiuyue WangDepartment of Respiratory and Critical Care Medicine, First Hospital of China Medical University, Shenyang, China.
Xiu GuDepartment of Pulmonary and Critical Care Medicine, Fourth Hospital of China Medical University, Shenyang, China.
Xiaoming ZhouRespiratory Department, Center for Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. zhouxmcmu@163.com.
China Medical University · CNFu Wai Hospital · CNInstitute of Applied Ecology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmall airway remodelling is a vital characteristic of chronic obstructive pulmonary disease (COPD), which is mainly caused by epithelial barrier dysfunction and epithelial-mesenchymal transition (EMT). Recent studies have indicated that histone deacetylase 6 (HDAC6) plays an important role in the dysregulation of epithelial function. In this study, we investigated the therapeutic effects and underlying mechanisms of an inhibitor with high selectivity for HDAC6 in COPD.

methodsCigarette smoke (CS) exposure was used to establish a CS-induced COPD mouse model. CAY10603 at doses of 2.5 and 10 mg/kg was injected intraperitoneally on alternate days. The protective effects of CAY10603 against CS-induced emphysema, epithelial barrier function and small airway remodeling were evaluated using hematoxylin and eosin (H&E) staining, Masson's trichrome staining, immunohistochemical staining, and western blot. The human lung bronchial epithelial cell line (HBE) was used to elucidate the underlying molecular mechanism of action of CAY10603.

resultsHDAC6 levels in the lung homogenates of CS-exposed mice were higher than that those in control mice. Compared to the CS group, the mean linear intercept (MLI) of the CAY10603 treatment group decreased and the mean alveolar number (MAN)increased. Collagen deposition was reduced in groups treated with CAY10603. The expression of α-SMA was markedly upregulated in the CS group, which was reversed by CAY10603 treatment. Conversely, E-cadherin expression in the CS group was further downregulated, which was reversed by CAY10603 treatment. CAY10603 affects the tight junction protein expression of ZO-1 and occludin. ZO-1 and occludin expression were markedly downregulated in the CS group. After CAY10603treatment, the protein expression level of ZO-1 and occludin increased significantly. In HBE cells, Cigarette smoke extract (CSE) increased HDAC6 levels. CAY10603 significantly attenuated the release of TGF-β1 induced by CSE. CAY10603 significantly increased the E-cadherin levels in TGF-β1 treated HBE cells, while concurrently attenuated α-SMA expression. This effect was achieved through the suppression of Smad2 and Smad3 phosphorylation. CAY10603 also inhibited TGF-β1 induced cell migration.

conclusionsThese findings suggested that CAY10603 inhibited CS induced small airway remodelling by regulating epithelial barrier dysfunction and reversing EMT via the TGF-β1/Smad2/3 signalling pathway.

Indexed as

CarbamatesCigarette SmokingOxazolesPulmonary Disease, Chronic ObstructiveAirway RemodelingAnimalsCadherinsEpithelial CellsEpithelial-Mesenchymal TransitionHistone Deacetylase 6HumansMiceOccludinTobacco ProductsTransforming Growth Factor beta1CadherinsCarbamatesCAY10603HDAC6 protein, humanHistone Deacetylase 6OccludinOxazolesTransforming Growth Factor beta1Airway remodellingCAY10603Cigarette smokeCOPDHDAC6

Identifiers

PMID38317159
PMCPMC10840206
OpenAlexW4391535895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.